A Phase 2 interventional study of LUM001 (Maralixibat) in Alagille Syndrome, sponsored by Mirum Pharmaceuticals, Inc.. Completed at 11 sites in 2 countries. Open to participants aged 1 Year to 18 Years. Per ClinicalTrials.gov, last updated 2021-07-01.
Sponsored by Mirum Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. — 2 open to participants now, 2 under way, none of them phase 3. Alagille Syndrome · Mirum Pharmaceuticals, Inc..
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., this one is the only one that started in 2015, is one of 6 in phase 2, and was the 4th registered.
31 studies on the registry are indexed under Alagille Syndrome; 11 are open to participants now.
Browse Alagille Syndrome studies →2 of the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc. are open now, in 9 countries. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Belgium, France, Germany and 5 more countries
Ages 2 mo+
Mirum Pharmaceuticals, Inc. · Sites in United States
By country, each count listing its studies:
Of the 10 Alagille Syndrome studies recruiting now, 7 (70%) set no upper age limit and 3 (30%) stop at 75 or younger; 9 take children under 18; none take healthy volunteers.
This study: 1 Year to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2015.
This study's enrollment of 34 is close to the median of 31 across 15 interventional studies indexed under Alagille Syndrome.
Median enrollment 31 across the 7 interventional studies, 47 across the 2 observational. Of the 7 that completed or were terminated, 6 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
Mirum Pharmaceuticals, Inc. is the lead sponsor of 40 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 11 (92%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 10 studies in Alagille Syndrome by Mirum Pharmaceuticals, Inc., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicentre, extension study of LUM001 in children diagnosed with Alagille Syndrome who have completed participation in a core LUM001 treatment protocol. The primary objective is to evaluate long-term safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 on the biochemical markers and pruritus associated with Alagille Syndrome.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sexually active females must be prepared to use an effective method of during the trial.
Effective methods of contraception are considered to be:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participant will receive LUM001 also known as Maralixibat (MRX) administered orally once per day.
Drug: LUM001 (Maralixibat)
Dosing of LUM001 also known as Maralixibat (MRX) with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the participant and up to a maximum daily dose of 280 micrograms per kilogram (mcg/kg).
Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA)
This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.
Time frame: Baseline to Week 48
Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA)
The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.
Time frame: Baseline to week 216
Change From Baseline to Week 218 in Pruritus
This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.
Time frame: Baseline to Week 218
Change From Baseline to Week 216 in Alanine Aminotransferase
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.
Time frame: Baseline to week 216
Change From Baseline to End of Treatment in Alkaline Phosphatase
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.
Time frame: Baseline to Week 216
Change From MRX Baseline to Week 216 in Aspartate Aminotransferase
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.
Time frame: Baseline to week 216
Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.
Time frame: Baseline to week 216
Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score
This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.
Time frame: Baseline to Week 216
Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.
Time frame: Baseline to Week 216
Mean Change From MRX Baseline to Week 216 in Total Bilirubin
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.
Time frame: Baseline to week 216
Mean Change From MRX Baseline to Week 216 in Direct Bilirubin
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.
Time frame: Baseline to week 216
| Milestone | LUM001 (Maralixibat) |
|---|---|
| Started | 34 |
| Completed | 26 |
| Not completed | 8 |
| Withdrew: Adverse event | 4 |
| Withdrew: Withdrawal by caregiver | 2 |
| Withdrew: Did not consent to protocol amendment 4 | 2 |
| Milestone | LUM001 (Maralixibat) |
|---|---|
| Started | 26 |
| Completed | 20 |
| Not completed | 6 |
| Withdrew: Adverse event | 3 |
| Withdrew: Progressive disease | 2 |
| Withdrew: Non-compliance with study drug | 1 |
This primacy efficacy endpoint is the mean change from MRX baseline to week 48 in fasting sBA levels.
| μmol/L | MRX Baseline Value | Maralixibat Week 48 Values |
|---|---|---|
| Change From MRX Baseline to Week 48 in Fasting Serum Bile Acid (sBA) | 223.62 ± 205.041 | 157.35 ± 178.538 |
The secondary endpoint of this study was the mean change from MRX baseline to week 216 fasting in sBA levels.
| μmol/L | Maralixibat Baseline Values | Week 216 |
|---|---|---|
| Change From MRX Baseline to Week 216 in Fasting Serum Bile Acid (sBA) | 223.62 ± 205.041 | 118.81 ± 126.878 |
This secondary efficacy endpoint is the mean change from MRX baseline over time to week 218 in pruritus as measured by ItchRO(Obs) weekly average morning severity score. ItchRO scores range from 0 to 4; the higher score indicates increasing itch severity (0 = none; 4 = very severe). Results reported here are the long-term results.
| score on a scale | Maralixibat Baseline Values | Week 218 |
|---|---|---|
| Change From Baseline to Week 218 in Pruritus | 2.533 ± 0.8423 | 0.429 ± 0.8571 |
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALT levels.
| U/L | MRX Baseline Value | Week 216 Values |
|---|---|---|
| Change From Baseline to Week 216 in Alanine Aminotransferase | 152.9 ± 82.26 | 222.4 ± 126.53 |
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in ALP levels.
| U/L | MRX Baseline Value | Week 216 Values |
|---|---|---|
| Change From Baseline to End of Treatment in Alkaline Phosphatase | 598.8 ± 199.89 | 528.3 ± 221.93 |
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in AST levels.
| U/L | MRX Baseline Value | Week 216 |
|---|---|---|
| Change From MRX Baseline to Week 216 in Aspartate Aminotransferase | 149.7 ± 88.27 | 231.4 ± 122.26 |
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in clinician xanthoma severity scores. It is based on a 0-4 scale to rate the number of lesions present and the degree to which the lesions interfere or limit activities. Clinician xanthoma severity scores range from 0 to 4, with a score of zero representing no evidence of xanthomatosis and a score of 4 representing xanthoma so severe that it is disabling.
| Points | MRX Baseline Value | Week 216 |
|---|---|---|
| Change From MRX Baseline to Week 216 in Clinician Xanthoma Severity Score | 0.9 ± 1.33 | 1.1 ± 1.68 |
This secondary efficacy endpoint is the mean change from MRX baseline over time to week 216/LOCF in pruritus as measured by the Clinician Scratch Scale (CSS). The Clinician Scratch Scale uses a 5-point scale, where 0 = none; 1 = rubbing or mild scratching when undistracted; 2 = active scratching without evident skin abrasions; 3 = abrasion evident; 4 = cutaneous mutilation, haemorrhage and scarring evident.
| Points | MRX Baseline Value | Week 216 |
|---|---|---|
| Change From Baseline to Week 216/LOFC Clinician Scratch Scale (CSS) Score | 2.9 ± 1.08 | 1.1 ± 1.07 |
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in GGT.
| U/L | MRX Baseline Value | Week 216 Values |
|---|---|---|
| Change From MRX Baseline to Week 216 in Gamma Glutamyltransferase | 493.5 ± 380.29 | 431 ± 235.35 |
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in total bilirubin.
| mg/dL | MRX Baseline Value | Week 216 |
|---|---|---|
| Mean Change From MRX Baseline to Week 216 in Total Bilirubin | 5.62 ± 6.420 | 5.39 ± 5.181 |
This secondary efficacy endpoint is the mean change from MRX baseline to week 216 in direct bilirubin.
| mg/dL | MRX Baseline Value | Week 216 Values |
|---|---|---|
| Mean Change From MRX Baseline to Week 216 in Direct Bilirubin | 3.541 ± 3.6433 | 3.714 ± 3.8369 |
Collected over Baseline to End of Treatment (Week 216). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LUM001 (Maralixibat) | 0/34 (0%) | 6/34 (17.6%) | 34/34 (100%) |
| Event | LUM001 (Maralixibat) |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/34 |
| HaematemesisGastrointestinal disorders | 1/34 |
| HaematocheziaGastrointestinal disorders | 1/34 |
| Autoimmune hepatitisHepatobiliary disorders | 1/34 |
| Chronic hepatic failureHepatobiliary disorders | 1/34 |
| Fungal infectionInfections and infestations | 1/34 |
| MalnutritionMetabolism and nutrition disorders | 1/34 |
| EpistaxisRespiratory, thoracic and mediastinal disorders | 1/34 |
| Event | LUM001 (Maralixibat) |
|---|---|
| Upper respiratory tract infectionInfections and infestations | 16/34 |
| PyrexiaGeneral disorders | 15/34 |
| DiarrhoeaGastrointestinal disorders | 13/34 |
| CoughRespiratory, thoracic and mediastinal disorders | 13/34 |
| HeadacheNervous system disorders | 12/34 |
| VomitingGastrointestinal disorders | 10/34 |
| NasopharyngitisInfections and infestations | 10/34 |
| Alanine aminotransferase increasedInvestigations | 10/34 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 9/34 |
| Aspartate aminotransferase increasedInvestigations | 8/34 |
In the lead-in Study LUM001-301, participants were randomized to receive either placebo or active drug (MRX). The last observation obtained before first dose of MRX (either for participants who received MRX or placebo LUM001-301) was used as the MRX baseline observation for all calculations of change. For participants who were assigned MRX in LUM001-301, results at each post-baseline analysis visit included up to 13 more weeks of treatment than participants who were assigned placebo.
| Age, Continuous(years of age) | Core Study Period |
|---|---|
| Mean | 7 ± 4.55 |
| Sex: Female, Male(Participants) | Core Study Period |
|---|---|
| Female | 14 |
| Male | 20 |
| Race (NIH/OMB)(Participants) | Core Study Period |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 1 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 27 |
| More than one race | 1 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Core Study Period |
|---|---|
| Canada | 4 |
| United States | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2015 to primary completion in Jun 2020, 62 months.
Results were first posted in Jun 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maralixibat